Hot or Not, Stock Market Edition: 06/30/2026
Happy Tuesday. Here’s what the Zen Ratings are smiling and frowning upon today:
- Hot: Is Bristol Myers Squibb (BMY) starting an uptrend? Plus, health information service provider Progyny (PGNY) gains serious momentum
- Not: Biotech player Crinetics Pharmaceuticals (CRNX) flashes warning signs;; gas utility Spire (SR) is stuck at a red light
P.S. Wednesday morning is fast approaching… That's when the Zen Investor portfolio will add 2 brand-new stock picks — including the #1 ranked stock in the entire Zen Ratings universe — selected through the same proven process responsible for 60+ triple-digit winners since 2023. Discover Zen Investor & Get 2 New Picks Wednesday Morning >
A note from our sponsors...
The Biggest Growth Stock of All Time? Its CEO expected this lab to grow 10-fold in 2026. Instead, it soared 80-fold in a single quarter. Nvidia, Amazon, and Google are all profiting from its explosive growth. Now it's your turn...🔥 HOT: General drug manufacturer Bristol Myers Squibb (BMY) appears to be gaining traction. The stock has gained a solid 5% in the past week, and signs indicate the trend could continue. The writing is on the wall: A slew of articles have recently highlighted BMY as a "safer" dividend buy and a top retirement income play, drawing attention from income-focused investors seeking stability. The company's discounted valuation and focus on specialty medicines are also attracting value investors. Supporting the bullish take, the stock was recently upgraded to a Zen Rating of A (Strong Buy), and currently ranks in the top 3% of the 4600+ stocks tracked based on a 115-factor review. It scores particularly well with an A grade for Value and B grades for AI, Safety, and Financials. With a combination of defensive characteristics, attractive valuation, and strong quality metrics, Bristol Myers appears to be a standout among large-cap pharmaceutical stocks.
🥶 NOT: Biotech player Crinetics Pharmaceuticals (CRNX) highlights an important investing lesson: good news doesn't always make a good stock. Despite securing European approval for its lead therapy and reporting encouraging early commercial demand, shares remain under pressure as investors question whether the company's valuation already reflects much of that optimism. Supporting the bear case, the stock is currently trading below its 50-day, 100-day, and 200-day moving averages, highlighting persistent technical weakness in investor sentiment.
As for the Zen Ratings, they paint a dismal picture. CRNX holds an F Zen Rating, placing it among the lowest-rated stocks in the system. It receives D grades for AI, Financials, Safety, and Sentiment. Until Crinetics proves it can consistently translate clinical success into meaningful revenue and earnings growth, the market appears unwilling to reward the story.
🔥 HOT: Health information service provider Progyny (PGNY) is benefiting from one of healthcare's fastest-growing trends: Employers are investing more heavily in fertility and family-building benefits to attract and retain talent. The company continues to expand its client base while existing customers increase utilization of its services, driving strong recurring revenue and reinforcing Progyny's leadership in a rapidly growing niche. And unlike many healthcare growth stories, Progyny combines that expansion with a profitable, asset-light business model and a strong balance sheet.
The fundamentals support the bullish outlook. PGNY earns an A Zen Rating, placing it in the top 4% of stocks tracked by WallStreetZen's 115-factor model. The company receives A grades for Financials and Sentiment along with a B for Safety, reflecting strong execution, growing institutional confidence, and financial strength. Bottom line: secular demand, expanding adoption, and elite fundamentals make Progyny one of the strongest growth stories in healthcare today.
🥶 NOT: Gas utility company Spire (SR) is is struggling to keep pace in a market that increasingly rewards earnings growth over stability. While regulated utilities can provide dependable income, Spire has reported three consecutive years of declining revenue, raising concerns about its long-term growth prospects. With limited catalysts to accelerate earnings and a business tied to the slow-moving regulated utility model, investors have increasingly looked elsewhere for better opportunities.
The weakening fundamentals are reflected in the ratings. SR recently fell to an F-rated Strong Sell in the Zen Ratings system, ranking among the market's weakest stocks. The company earns F grades for both Growth and Industry Rank along with D grades for Financials and Sentiment, signaling deteriorating business momentum and limited investor confidence. Bottom line: Spire may appeal to income-focused investors, but its sluggish growth profile and weak fundamentals make it difficult to recommend when stronger utility stocks are available.
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.